Immune cell therapy for B-cell cancer
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins (CD19 and CD70) on your cancer cells. It is for patients with B-cell cancers that didn't respond to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be older than 6 months.
- Your cancer cells must have a specific protein called CD19 or CD70 on their surface.
- You should be able to care for yourself and do daily activities (KPS score over 80).
- You should feel well enough to live at least 1 month (doctor's estimate).
- Your hemoglobin level must be above 80 g/L.
- You must be able to safely have blood cells collected (like a blood donation procedure).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a special cell therapy that targets two markers on cancer cells to treat certain blood cancers. It may help people whose cancer has not gotten better with other treatments.
This trial tests a new type of immune cell therapy (4SCAR19U T cells) designed to attack B-cell cancers. It may be an option if your cancer has the CD19 protein and you haven't had a prior CAR-T treatment that failed.
This trial tests a new car t-cell treatment for people with certain blood cancers that did not go away or came back after standard treatments. It aims to see if this therapy can help when other options have not worked.
This trial tests a new treatment using your own immune cells (T-cells) that are modified to find and attack cancer cells with a marker called CD22. It is for people with B-cell blood cancers that have come back or not responded to at least two prior treatments, including a type of immunotherapy called CAR T-cell therapy.
This trial tests a personalized cell therapy that uses your own immune cells, modified to better find and attack lymphoma cells. It may help when standard treatments have not worked.
This trial tests a type of immune therapy called CAR-T cells to treat autoimmune diseases. The treatment targets B cells, which are part of the immune system that can attack your own body in autoimmune conditions.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.